Enovis CORP

Enovis is a U.S.-based medical technology company focused on orthopedic and musculoskeletal care. It develops, manufactures, and distributes devices and services that support injury prevention, joint reconstruction, and rehabilitation, serving clinicians, distributors, and retail consumers across the care continuum.

9,8 %

59,8 %

−52,7 %

+6,7 %

2.02

1.04

— Enovis CORP
%
Prevention & Recovery52% Orthopedic bracing, supports, and rehabilitation products used to prevent injury and aid recovery.
Reconstructive implants38% Joint replacement and reconstructive implant systems for multiple anatomical sites.
Surgical productivity tools7% Instruments, workflow tools, and computer-assisted surgery solutions that support procedures.
Education and digital services3% Surgeon training, planning software, and digital tools that improve clinical execution.

Enovis sells to orthopedic specialists, surgeons, hospitals, ambulatory surgery centers, and other healthcare...

  • Orthopedic surgeons and specialistsprimary

    Buy reconstructive implants, surgical tools, and planning solutions to improve procedure outcomes.

  • Hospitals and ambulatory surgery centersprimary

    Purchase implant systems and productivity tools for joint replacement and orthopedic procedures.

  • Independent distributorssecondary

    Resell Enovis products into fragmented medical markets and expand geographic coverage.

  • Retail consumerssecondary

    Buy braces, supports, and recovery products for injury prevention and rehabilitation.

Enovis has a global footprint with production facilities in North America, Europe, North Africa, and Asia...

  • About 57-58% of sales are from the United States
  • Roughly 42-43% of sales come from outside the U.S.
  • Europe is the largest non-U.S. market for both segments
  • Asia-Pacific is the main secondary international region
  • Production facilities span North America, Europe, North Africa, and Asia

Enovis is focused on growth through innovation, commercial execution, and selective acquisitions that expand its...

01
Innovation-led product developmentmedium-term

New implants, surgical tools, and digital solutions support better outcomes and pricing power.

02
Acquisition-led expansionshort-term

Bolt-on deals add technology, geography, and channel coverage in fragmented markets.

03
International growthmedium-term

Europe and Asia-Pacific provide growth outside the mature U.S. market but add FX and execution risk.

Enovis depends on successful acquisition integration, product innovation, and execution in fragmented orthopedic...

high

Acquisition integration failure

Growth strategy relies heavily on bolt-on deals and prior acquisitions like Lima.

Scope
Could reduce synergies, delay product integration, and raise costs.
Materiality
high
high

Goodwill impairment

The company carries acquisition-related goodwill and intangibles and flagged an impairment indicator in Q3 2025.

Scope
A sustained share-price or market-cap decline can trigger charges.
Materiality
high
medium

Foreign exchange volatility

About 42-43% of sales are outside the U.S., mostly in Europe.

Scope
FX movements can change reported sales, gross profit, and operating expense.
Materiality
high
medium

Competitive pressure in orthopedic devices

Markets are fragmented and include larger rivals with greater resources.

Scope
Pricing, innovation, and brand strength affect share gains.
Materiality
high
medium

Cybersecurity and IT disruption

Medical-device operations depend on secure systems, vendors, and data.

Scope
Breaches could disrupt production, damage reputation, and create liability.
Materiality
medium
Goodwill and intangible asset impairment
Can produce large non-cash charges if assumptions or market value deteriorate
Seasonality
Quarterly comparisons can be uneven and working capital needs may fluctuate
Derivatives and hedging
Can materially change reported interest expense/income and cash flow presentation
Acquisition accounting and contingent consideration
Can create non-recurring charges, liabilities, and amortization expense

: 28/04/2026